drugset / Trial / NCT06940336

To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

NCT06940336

Phase 4 Recruiting 15 enrolled Qilu Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy

Timeline

Start
2025-06-19
Primary completion
2028-01
Completion
2028-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tafamidis Unknown 20 mg Oral